This study focuses on individuals living with Bronchiectasis, a condition where the airways in the lungs become permanently widened and damaged, making it difficult to clear mucus. This condition is often complicated by Pseudomonas aeruginosa colonization, which occurs when a specific type of bacteria lives in the airways for a long time. The purpose of the study is to evaluate the effectiveness and safety of a medication called AZD0292. This treatment is provided as a solution for infusion, which means it is delivered directly into the bloodstream through a needle or tube.

During the trial, participants are assigned to receive either AZD0292 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being administered until the study is finished. The research will monitor how the medication moves through the body, a process known as pharmacokinetics, and track any pulmonary exacerbations, which are sudden increases in symptoms like coughing or shortness of breath. Participants will be monitored over a period of time to observe how the treatment affects the frequency of these lung symptom flare-ups.